Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention

Cyclooxygenase (COX) inhibitors reduce colorectal adenoma recurrence by up to 45% and selenium supplementation may prevent colorectal cancer. Following colonoscopic adenoma resection, 1,600 men and women aged 40-80 years were randomized to celecoxib (400 mg daily), a selective COX-2 inhibitor, and/o...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Thompson, Patricia, Roe, Denise J., Fales, Liane, Buckmeier, Julie, Wang, Fang, Hamilton, Stanley R., Bhattacharyya, Achyut, Green, Sylvan, Hsu, Chiu-Hsieh, Chow, H-H. Sherry, Ahnen, Dennis J., Boland, C. Richard, Heigh, Russell I., Fay, David E., Martinez, Maria Elena, Jacobs, Elizabeth, Ashbeck, Erin L., Alberts, David S., Lance, Peter
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2012
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3518663/
https://ncbi.nlm.nih.gov/pubmed/23060037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-12-0204
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia